SLC5A2 and hydrops fetalis: Indeed, participants in the STEP‐HFpEF and SUMMIT trials were at relatively low risk, as evidenced by the limited number of HF events (38 and 55 hospitalizations, respectively),11, 13 compared with much higher event rates in trials of SGLT2 inhibitors and finerenone (i.e. DELIVER: 1872; FINEARTS‐HF: 1866).103, 104